Gilead Named to Dow Jones Sustainability World Index for Third Consecutive Year
11 Dezembro 2023 - 2:00PM
Business Wire
– Gilead Also Included on the Dow Jones
Sustainability North America Index; Rankings Reflect Gilead’s
Ongoing Commitment to Corporate Responsibility –
– DJSI World Highlights the Most Sustainable
Companies Around the World Based on Corporate Sustainability
Assessment –
Gilead Sciences, Inc. (Nasdaq: GILD) today announced the company
has once again been recognized as one of the most sustainable
pharmaceutical companies according to the Dow Jones Sustainability
World Index (DJSI World) for the third consecutive year. The
company was also included on the Dow Jones Sustainability North
America Index (DJSI North America). These rankings are based on an
in-depth analysis of Gilead’s sustainability performance and
highlight the company’s longstanding sustainable business practices
and transparency on environmental, social and governance (ESG)
issues.
“We are very pleased that Gilead’s commitment to corporate
responsibility is recognized once again with inclusion on the Dow
Jones Sustainability World Index,” said Daniel O’Day, Chairman and
Chief Executive Officer, Gilead Sciences. “By investing in
world-class science, driving access to our therapies and addressing
societal barriers to care, Gilead’s work is helping to create a
healthier world for all people.”
Gilead’s ESG strategy aims to position the company as an
employer of choice that delivers shareholder value in a
sustainable, responsible manner. Gilead’s focus on scientific
innovation and sustainable business practices is centered around
the needs of patients, employees and communities around the world.
Examples of Gilead’s commitment to ESG include:
- Expanding health equity around the world through programs that
promote health system sustainability, strengthen infrastructure and
provide education and financial support
- Increasing access to medicines in low- and lower-middle income
countries, including voluntary licensing for Gilead’s HIV,
hepatitis C and COVID-19 treatments
- Creating an inclusive workplace that is representative of the
diverse communities the company serves
- Continuing to evolve the company’s environmental sustainability
program and setting ambitious goals that further embed
sustainability into the business across four focus areas of carbon,
water, waste and product
The DJSI World applies a transparent, rules-based constituent
selection process based on the companies’ S&P Global ESG Score
resulting from the annual S&P Global Corporate Sustainability
Assessment (CSA). The CSA consists of a rigorous questionnaire
assessing both public and non-public data submitted by
participating companies.
DJSI North America comprises North American sustainability
leaders as identified by S&P Global through the CSA. It
represents the top 20% of the largest 600 North American companies
in the S&P Global BMI based on long-term economic,
environmental and social criteria.
Details on Gilead’s ESG commitments, goals and progress can be
found in the company’s Environmental Social Governance Impact
Report, which is based on internationally recognized guidelines
from the Global Reporting Initiative, the Sustainability Accounting
Standards Board, the Taskforce on Climate Related Financial
Disclosures and the United Nations Sustainable Development Goals.
Learn more about Gilead’s commitment to ESG and corporate
responsibility at https://www.gilead.com/purpose/esg.
About Gilead Sciences
Gilead Sciences, Inc. is a biopharmaceutical company that has
pursued and achieved breakthroughs in medicine for more than three
decades, with the goal of creating a healthier world for all
people. The company is committed to advancing innovative medicines
to prevent and treat life-threatening diseases, including HIV,
viral hepatitis, COVID-19, and cancer. Gilead operates in more than
35 countries worldwide, with headquarters in Foster City,
California.
Gilead and the Gilead logo are registered
trademarks of Gilead Sciences, Inc., or its related companies.
For more information about Gilead, please visit
the company’s website at www.gilead.com, follow Gilead on Twitter
(@Gilead Sciences) or call Gilead Public Affairs at 1-800-GILEAD-5
or 1-650-574-3000.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231210138501/en/
Jacquie Ross, Investors Investor_relations@gilead.com
Meaghan Smith, Hayley Home, Media Public_affairs@gilead.com
Gilead Sciences (NASDAQ:GILD)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Gilead Sciences (NASDAQ:GILD)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024